Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601667 | 0.81 | CHRNB2 (0.42) | CHRNB2CHRNA4MAOBCHRNB1CHRNB4 | |
| SCHEMBL11475129 | 0.78 | MAOB (0.44) | CHRNB2CHRNA4MAOBCYP3A4CYP2A6 | |
| SCHEMBL30453732 | 0.78 | MAOB (0.44) | CHRNB2CHRNA4MAOBCYP3A4CYP2A6 | |
| SCHEMBL7394763 | 0.78 | S1PR4 (0.46) | MAOBCYP3A4CYP2A6MAOAMAPT | |
| SCHEMBL11479292 | 0.78 | LTA4H (0.54) | MAOBCYP3A4CYP2A6MAOAMAPT | |
| SCHEMBL8325639 | 0.76 | ALDH1A1 (0.52) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL19616353 | 0.76 | MAPT (0.48) | MAOBCYP3A4CYP2A6MAOAMAPT | |
| SCHEMBL31461865 | 0.76 | ALDH1A1 (0.52) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL17672492 | 0.76 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL10347560 | 0.75 | MAPT (0.56) | MAOBCYP3A4CYP2A6MAOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185544-B1 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2185544-B1 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8846675-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846675-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | CYMABAY THERAPEUTICS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120322804-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322804-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2012-12-20 | — | — | US | disclosed |
| US-8183381-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183381-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2185544-A2 | N-AZACYCLIC SUBSTITUTED PYRROLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | Metabolex Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009014910-A2 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009014910-A2 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | CHRNB2 591/4885CHRNA4 705/4885MAOB 993/4885 |
| US-20120322804-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | CHRNB2 591/4885CHRNA4 705/4885MAOB 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.